

# Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

## Notice of Change in Dividend Policy

---

**TOKYO, November 6, 2023** – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi) announced that the Company has resolved at the board meeting held on November 6, 2023, to change its dividend policy for the fiscal year ending March 31, 2025, and thereafter as follows.

1. Reason for Change

The Company has set a minimum dividend per share and introduced a consolidated dividend payout ratio in line with its policy of providing appropriate profit returns based on business performance while maintaining the existing approach to realize management that is conscious of the cost of capital and share price.

2. Details of Dividend Policy

1) Policy before change (conventional policy)

The Company's basic policy is to continue to pay stable dividends while comprehensively taking into consideration such factors as securing funds for long-term business development.

2) Policy after change

The target consolidated dividend payout ratio is 30% as a performance-linked profit distribution. The Company's policy is set the minimum dividend per share at 30 yen per share per year to maintain stable dividends while linking profit distribution to business performance.

3. Effective period of change

Effective from the fiscal year ending March 31, 2025.

(For the dividend for the fiscal year ending March 31, 2024, please refer to the " Notice of Revisions of Dividends from Surplus (Increase in Interim Dividend) and Year-end Dividend Forecast" announced on the same day.)

---

### Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)